$XGN Exagen — the autoimmune panel that reads complement fragments, and the quarter that proved the model works

Autoimmune disease is not a disease. It is roughly eighty of them, sharing one set of symptoms and one screening test that says almost nothing. $XGN sells the thing that comes next: a single blood draw that measures forty-odd immune markers at once and returns a probability rather than a shrug.

Autoimmune medicine is the last large field still triaged on single-analyte serology designed in the 1950s, and it fails in public: 41 million Americans screen antibody-positive on a test that identifies perhaps 3 million real patients, and a lupus diagnosis still takes six years. $XGN is the only commercial lab running cell-bound complement activation products — fragments welded onto circulating cells that record immune activity cumulatively instead of as a spot depletion — which lifts lupus sensitivity from 44% to 80% at 98% specificity.

That chemistry is patented to 2035 and has just extended into seronegative rheumatoid arthritis, where roughly 30% of genuine patients are invisible to standard antibodies. The bet is on the platform compounding: myositis ships in early 2027 into the channel's most-requested gap, a product roughly every twelve months behind it, and a pipeline that moves from one-time diagnosis into recurring disease-activity monitoring — with the operating model having just proven it scales.

No single autoantibody is specific to a single disease. Anti-dsDNA leans lupus; ACPA leans rheumatoid arthritis; SSa/SSb lean Sjögren's — but they overlap heavily, and a patient can be positive for several while having one condition or none.

$XGN's differentiator is a class of markers almost nobody else runs commercially: CB-CAPs — cell-bound complement activation products. Classical serology measures complement proteins in serum (C3, C4) and infers activation from their depletion. CB-CAPs instead measure the fragments left covalently stuck to circulating cells after activation: EC4d on erythrocytes, BC4d on B-lymphocytes, and since 2025 TC4d on T-cells. Because red cells live about 120 days, the fragments they carry are a cumulative record rather than a spot reading. The test measures the exhaust, not the fuel gauge.

Two 2025 additions matter commercially. T-cell markers raise lupus sensitivity further and are rarely present in other rheumatic diseases. Anti-RA33 and anti-PAD4 attack a genuinely unserved population — seronegative rheumatoid arthritis, patients with real RA who test negative on ACPA and rheumatoid factor. Management claims these detect 30% of seronegative RA patients.

R&D is small in absolute terms — $1.4M in Q2, $6.3M in FY25 — which is the honest weak spot in a technology story. What it buys is a deliberately sequenced pipeline rather than a moonshot. The near-term item is myositis, the first standalone product in years, on track for early 2027.

Execution risk is lower than a typical launch. The two new laboratory platforms are already installed and analytically validated; clinical validation is in process; the sales force trains at the end of Q3 and sells it across all 45 territories to the same rheumatologist call point. Reimbursement launches on established methodology-based CPT codes rather than a novel-code fight.

Underneath sits the metric management actually runs on: trailing-twelve-month ASP of $446, up $18 year over year and the 13th consecutive quarter of growth, from $284 at the end of 2022 — a 57% increase achieved with a static Medicare rate, entirely through commercial-payer appeals, administrative-law-judge hearings and evidence submission.

The ASP engine may be a collections harvest, not a pricing re-rate. Q2's ASP included over $1M collected on claims more than 360 days old; H1 collected $2.3M of such recoveries against $1.5M in all of FY25. That is a stock of aged claims being worked down, not a flow.

The Q2 print did the one thing the bear case required it to fail at — it restored gross margin and held opex while accelerating revenue. The business is now roughly one good quarter from sustained cash breakeven. Constructive, with the entry disciplined rather than immediate: the stock is 38% higher in a day with RSI at 78 and a GEX call wall at $7.50, so the risk is paying for six quarters of progress in one session. A pullback toward the reclaimed 200-day (~$5.20) is the attractive accumulation zone.